SPRY
ARS Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
2.42 / 10
Underperform
ARS Pharmaceuticals' fundamental profile is concerning, scoring only 2.4/10. Key weaknesses include a Days Sales Outstanding of 107.2 days (group 3, score 0/3), signaling slow receivable collection, and a negative Profit-MV (-1.45) despite strong revenue growth (2088% YoY). The Interest Coverage Ratio of 15.48 is adequate but insufficient to offset other deficits. PB-ROE (1.59) and Asset-MV (-0.50) are also unfavorable, placing SPRY in lower-performing factor groups. Overall, the company's balance-sheet and profitability metrics suggest limited fundamental strength.
Analysis Checks(6/10)
Revenue-MV
Value-1.45
Score1/3
Weight12.21%
1M Return4.24%
Value-1.45
Score1/3
Weight12.21%
1M Return4.24%
Days sales outstanding
Value107.21
Score0/3
Weight-10.75%
1M Return-5.18%
Value107.21
Score0/3
Weight-10.75%
1M Return-5.18%
Net income-Revenue
Value-0.17
Score2/3
Weight24.28%
1M Return8.45%
Value-0.17
Score2/3
Weight24.28%
1M Return8.45%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-2.43%
1M Return-1.11%
Value15.48
Score2/3
Weight-2.43%
1M Return-1.11%
Asset-MV
Value-0.50
Score1/3
Weight17.75%
1M Return6.68%
Value-0.50
Score1/3
Weight17.75%
1M Return6.68%
Total operating revenue (YoY growth rate %)
Value2088.12
Score2/3
Weight2.60%
1M Return1.11%
Value2088.12
Score2/3
Weight2.60%
1M Return1.11%
Profit-MV
Value0.46
Score2/3
Weight24.25%
1M Return8.45%
Value0.46
Score2/3
Weight24.25%
1M Return8.45%
PB-ROE
Value1.59
Score0/3
Weight7.24%
1M Return2.72%
Value1.59
Score0/3
Weight7.24%
1M Return2.72%
Operating revenue (YoY growth rate %)
Value2088.12
Score2/3
Weight1.00%
1M Return0.43%
Value2088.12
Score2/3
Weight1.00%
1M Return0.43%
Cash-MV
Value-0.07
Score2/3
Weight23.85%
1M Return8.41%
Value-0.07
Score2/3
Weight23.85%
1M Return8.41%
Revenue-MV
Value-1.45
Score1/3
Weight12.21%
1M Return4.24%
Value-1.45
Score1/3
Weight12.21%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value2088.12
Score2/3
Weight2.60%
1M Return1.11%
Value2088.12
Score2/3
Weight2.60%
1M Return1.11%
Days sales outstanding
Value107.21
Score0/3
Weight-10.75%
1M Return-5.18%
Value107.21
Score0/3
Weight-10.75%
1M Return-5.18%
Profit-MV
Value0.46
Score2/3
Weight24.25%
1M Return8.45%
Value0.46
Score2/3
Weight24.25%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight24.28%
1M Return8.45%
Value-0.17
Score2/3
Weight24.28%
1M Return8.45%
PB-ROE
Value1.59
Score0/3
Weight7.24%
1M Return2.72%
Value1.59
Score0/3
Weight7.24%
1M Return2.72%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-2.43%
1M Return-1.11%
Value15.48
Score2/3
Weight-2.43%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value2088.12
Score2/3
Weight1.00%
1M Return0.43%
Value2088.12
Score2/3
Weight1.00%
1M Return0.43%
Asset-MV
Value-0.50
Score1/3
Weight17.75%
1M Return6.68%
Value-0.50
Score1/3
Weight17.75%
1M Return6.68%
Cash-MV
Value-0.07
Score2/3
Weight23.85%
1M Return8.41%
Value-0.07
Score2/3
Weight23.85%
1M Return8.41%
Is SPRY fundamentally strong?
- SPRY scores 2.42/10 on fundamentals and holds a Premium valuation at present. Backed by its -64.27% ROE, -56.06% net margin, -20.65 P/E ratio, 6.71 P/B ratio, and -62.00% earnings growth, these metrics solidify its Underperform investment rating.
